摘要
CD_(56)抗原是自然杀伤细胞表面的特异性标志,但随后被发现亦表达于急性髓系白血病(AML)细胞,CD_(56)在AML各亚型中表达不同,主要表达在M_2、M_5中,在M_3中亦有表达,对t(8;21)阳性AML具有独立的预后影响因素,与M_3的复发密切相关,对M_5独特临床特征也有一定的影响;CD_(56)与P糖蛋白、CD_(11b)的表达有关,导致机体的多药耐药、髓外浸润从而导致不良的预后;由p48和由Runx1基因诱导下的核因子κB、Bcl-2旁路可以为CD_(56)阳性的高风险AML患者提供新的治疗靶点;CD_(56)的检测已应用于微小残留病灶的监测,对临床治疗和预后判断具有重要意义。
CD56 antigen is a specific marker of natural killing cell surface, which is subsequently found to be expressed in acute myeloid leukemia（AML） ceils. The expression of CDs6 in different AML subtypes is different that it is mainly expressed in M5 and M2 ,also in M3. CD^6 is an independent prognostic factor for t （8;21） positive AML, which is closely related to the recurrence of M3, and has a certain effect on the unique clinical characteristics of MS. CD56 is related to the expression of P glyeoprotein and CDllb, which could result in multi-drug resistance and extramedullary infiltration causing poor prognosis; the NF-KB and Bcl-2 pathway induced by p48 and Runxl gene could be a new therapeutic target for CD56 positive high risk AML patients. And the detection of CD56 has been applied to the monitoring of minimal residual disease, which is of great significance for the clinical treatment and prognosis judgment.
出处
《医学综述》
2016年第12期2345-2348,共4页
Medical Recapitulate
基金
青海大学附属医院中青年科研基金(ASRF-2014-14)
